Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
Finotonlimab（PD-1抑制剂）联合贝伐单抗（贝伐单抗生物类似药）作为晚期肝细胞癌的一线治疗方案：一项随机2/3期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02333-5
Zhao, Chuanhua; Zhang, Yanqiao; Wang, Gang; Zheng, Jinfang; Chen, Weiqing; Lu, Zheng; Zhuang, Li; Gu, Shanzhi; Han, Lei; Zheng, Zhendong; Yu, Zujiang; Yang, Yongsheng; Sun, Hongmei; Wei, Xiaoyong; Cheng, Ying; Lin, Hailan; Zhu, Bo; Wu, Guicheng; Lei, Kaijian; Wang, Wei; Wang, Yuwen; Chen, Kehe; Xu, Ximing; Zheng, Cuiping; Bi, Yanzhi; Ding, Sijuan; Zhang, Jingdong; Li, Wei; Liu, Hailong; Wang, Jun; Liu, Xianling; Du, Yangfeng; Cai, Lianming; Wang, Jingran; Luo, Zhanxiong; Xing, Baocai; Shen, Jie; Yang, Lin; Wu, Jianbing; Jiang, Ou; Peng, Zhigang; Liu, Xiuli; Cao, Bangwei; Shen, Liangfang; Xu, Aibing; Li, Aimin; Chen, Shaojun; Fu, Ting; Chen, Jian; Jin, Chuan; Zhang, Lei; Lv, Jun; Zhang, Chengwu; Zhang, Xiaoman; Wang, Yu; Su, Huo; Zhou, Qiang; Gai, Wenlin; Xie, Liangzhi; Xu, Jianming
